Compare Kraft Heinz Co (KHC) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Kraft Heinz Co trades at $22.79 (market cap $26.60B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Kraft Heinz Co is far larger — about 27.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Kraft Heinz Co pays a 7.13% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| KHC | MRVI | |
|---|---|---|
Market Cap | $26.60B | $972.90M |
Volume | 11,136,448 | 4,325,710 |
Sector | Consumer Staples | Health |
52-Week High | $27.62 | $9.00 |
52-Week Low | $21.21 | $2.83 |
Typical Hold Time | 129 Days | 0 Days |
Enterprise Value | $42.92B | $1.08B |
Dividend Yield | 7.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $22.70, up 1.11% on the day, with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals, including a negative net income margin of -13.64% for 2025 but a low P/B of 0.74, suggesting potential undervaluation. Recent news highlights the company's $700 million reinvestment plan and new product launches like Philadelphia cream cheese flavors to revive brands amid volume challenges.
The outlook remains cautious due to persistent profitability issues and high debt, though the dividend yield near 6.5% and analyst consensus price target of $24.11 offer some upside. Key risks include execution of the turnaround strategy and competitive pressures in the consumer goods sector.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
